GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Current Accrued Expense

Pharmaresearch Bio Co (XKRX:217950) Current Accrued Expense : ₩0 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co Current Accrued Expense?

Pharmaresearch Bio Co's Current Accrued Expense for the quarter that ended in Dec. 2023 was ₩0 Mil.


Pharmaresearch Bio Co Current Accrued Expense Historical Data

The historical data trend for Pharmaresearch Bio Co's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co Current Accrued Expense Chart

Pharmaresearch Bio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
Get a 7-Day Free Trial - - - - -

Pharmaresearch Bio Co Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense Get a 7-Day Free Trial - - - - -

Pharmaresearch Bio Co Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Pharmaresearch Bio Co Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaresearch Bio Co (XKRX:217950) Business Description

Traded in Other Exchanges
N/A
Address
641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494
Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines